Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Genetic-Tailored AntiThrombotic Strategy
- Development stage
- Unknown
- Lead developer
- Texas Cardiac Arrhythmia Research Foundation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The Genetic-Tailored AntiThrombotic Strategy is a personalized therapeutic regimen developed by the Texas Cardiac Arrhythmia Research Foundation for the prevention of device-related thrombosis (DRT) in patients with atrial fibrillation undergoing percutaneous left atrial appendage occlusion (LAAO). Evaluated in the FADE-DRT Phase 4 trial, the strategy involves the administration of aspirin in combination with either clopidogrel or a half-dose novel oral anticoagulant (NOAC), with the choice of the second agent determined by the patient's CYP2C19 genotype. This approach aims to optimize the balance between thrombotic prevention and bleeding risk by accounting for genetic variations that affect the metabolism and efficacy of antiplatelet therapy.
- Other names
- FADE-DRT Genetic-Tailored StrategyCYP2C19 Genotype-Guided Antithrombotic TherapyCYP-2C19 Genotype-Guided Antithrombotic TherapyCYP 2C19 Genotype-Guided Antithrombotic Therapy
02
Targets
P2Y12 (Purinergic P2Y12 receptor)PGHS-1 (Prostaglandin G/H Synthase 1)F10 (Factor Xa)F2 (Thrombin)
Beyond the preview
Go deeper on Genetic-Tailored AntiThrombotic Strategy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genetic-Tailored AntiThrombotic Strategy.